Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Sapanisertib (Primary) ; Serabelisib (Primary)
  • Indications Advanced breast cancer; Brain metastases; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 29 Jul 2024 Status changed from active, no longer recruiting to completed.
    • 14 Jul 2022 Preliminary efficacy results(n=19) of Phase I dose escalation study assessing the safety and efficacy of paclitaxel, sapanisertib, and serabelisib in Patients with previously treated advanced solid tumors published in the Gynecologic Oncology.
    • 24 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top